No recommendation
No news or research item is a personal recommendation to deal. Hargreaves Lansdown may not share ShareCast's (powered by Digital Look) views.
(Sharecast News) - Eli Lilly said on Thursday that it has agreed to buy AtaiBeckley, a clinical-stage biopharmaceutical company developing therapeutics for mental health conditions, for $2.8bn.
AtaiBeckley's lead asset, BPL-003 (mebufotenin benzoate), is a synthetic form of 5-MeO-DMT administered intranasally for treatment-resistant depression, which affects millions of people in the US.
Under the terms of the deal, Lilly will pay $6.75 per share in cash on closing, plus up to $2.50 per share in the form of a Contingent Value Right (CVR) entitling the holder to additional cash payments upon the achievement of specified development and regulatory milestones related to drug programs.
"Treatment-resistant depression persists even after multiple treatments have failed. Millions of people are still searching for relief and desperately need a therapy that works," said Carole Ho, executive vice president and president, Lilly Neuroscience. "Advancing AtaiBeckley's investigational therapies gives us a real chance to change that."
Lily noted that in a Phase 2b study, BPL-003 demonstrated rapid and durable reductions in depressive symptoms following an in-clinic visit lasting approximately two hours on average, with beneficial effects persisting for months.
BPL-003 has been granted Breakthrough Therapy Designation by the US Food and Drug Administration and has initiated Phase 3 activities.
The value of investments can go down in value as well as up, so you could get back less than you invest. It is therefore important that you understand the risks and commitments. This website is not personal advice based on your circumstances. So you can make informed decisions for yourself we aim to provide you with the best information, best service and best prices. If you are unsure about the suitability of an investment please contact us for advice.